A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease

Trial Profile

A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease

Recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Alglucosidase alfa (Primary)
  • Indications Glycogen storage disease type II
  • Focus Pharmacokinetics
  • Acronyms PAPAYA
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 16 Mar 2017 Planned End Date changed from 1 Feb 2018 to 1 Aug 2018.
    • 16 Mar 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Aug 2018.
    • 11 Aug 2016 Planned End Date changed from 1 Jan 2018 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top